Livzon approves 2024 results, greenlights A-share buyback continuation

Livzon Pharmaceutical Group Co., Ltd. (SZSE:000513) announced the resolutions passed at its 2024 Annual General Meeting of Shareholders, the First A Shareholders Class Meeting in 2025, and the First H Shareholders Class Meeting in 2025. Key approvals included the 2024 Board of Directors' Report, the 2024 Supervisory Board Report, and the 2024 Financial Statements. A profit distribution proposal was approved, earmarking a cash dividend of CNY 11.00 per 10 shares. Shareholders also authorized the board to repurchase H shares and continue the A-share buyback program. The company's financial statements reported total voting shares of 469,185,417, with at least 98% of shareholders voting in favor for the approvals. The group also approved plans to continue buyback of A shares.